RNS Number : 7222U
Acambis PLC
19 May 2008
Interim Management Statement
Cambridge, UK and Cambridge, Massachusetts - 19 May 2008 - Acambis plc (Acambis) (LSE:
ACM) publishes its Interim Management Statement
for the period 1 January 2008 to 18 May 2008.
On 23 April 2008, Acambis announced that it had been awarded a $425m (c. £212m),
ten-year contract by the US Government agency, the
Centers for Disease Control and Prevention, to provide it with a US-based warm-base
manufacturing capability for Acambis' ACAM2000* smallpox
vaccine. On the same date, Acambis announced a proposed fundraising of approximately £40m,
net of expenses, through an underwritten Placing
and Open Offer of 37,715,811 New Ordinary Shares at a price of 115p per New Ordinary Share,
which was at a discount of 5.3% to the middle
market price of 121.50p on the last practicable date before the announcement but was at a
premium to the average closing price for the five
business days prior to the announcement of 113.85p.
The Extraordinary General Meeting in relation to this Placing and Open offer is due to
take place on 20 May 2008. In addition, on 23
April 2008, Acambis also announced its preliminary results for the year ended 31 December 2007
and provided a trading update to the market
for the year to date.
Acambis today confirms that the trading performance and financial position of the Company
and its operations have continued to be in
line with the Board's expectations since 23 April 2008.
-ends-
Enquiries:
Acambis plc
Ian Garland, Chief Executive Officer
Elizabeth Jones, Chief Financial Officer
Lyndsay Wright, VP, Communications and IR
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Annabel Entress
Tel: +44 (0) 20 7404 5959
About Acambis
Acambis is a leading vaccine company developing novel vaccines that address significant
unmet medical needs or substantially improve
standards of care. ChimeriVax*-JE, Acambis' most advanced product in its development-stage
pipeline, has to date shown an excellent safety
and efficacy profile following pivotal Phase 3 trials. It is currently undergoing paediatric
trials in the endemic region and is partnered
with Sanofi Pasteur. Acambis' proprietary ChimeriVax* technology, developed in association
with St Louis University, has also been used to
develop ChimeriVax*-West Nile, which is undergoing Phase 2 clinical testing, making it the
most advanced investigational vaccine against the
West Nile virus. Acambis has established a global collaboration with Sanofi Pasteur for
further development and commercialisation of the
vaccine. ChimeriVax* has also been applied to development of Sanofi Pasteur's tetravalent
dengue vaccine, which has successfully
demonstrated proof-of-concept in a Phase 2 trial by generating 100% seroconversion to all four
dengue virus serotypes.
Acambis' ACAM-CDIFF* is the only vaccine in development against Clostridium difficile
bacteria, a leading cause of hospital-acquired
infections. C. difficile is estimated to cause at least 360,000 cases of C.difficile-associated disease in the US alone, and annual costs
to US and European healthcare systems are estimated to be in excess of $7bn a year. Acambis'
influenza programme aims to develop a universal
vaccine against influenza, for which a universal 'A' strain vaccine, ACAM-FLU-A*, was recently
tested in a Phase 1 trial and pre-clinical
challenge study. Acambis is currently undertaking pre-clinical testing of a vaccine candidate,
dl5-29, against genital herpes.
Acambis is recognised internationally as the leading producer of smallpox vaccines for
emergency-use stockpiles held by the US
Government and several other governments around the world. Acambis developed its ACAM2000*
smallpox vaccine under contracts with the US
Government.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the
London Stock Exchange (ACM). More information
is available at www.acambis.com.
"Safe Harbour" statement
Statements contained within this news release may contain forward-looking comments, which
involve risks and uncertainties that may cause
actual results to vary from those contained in the forward-looking statements. In some cases,
you can identify such forward-looking
statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans',
'anticipates', 'believes', 'estimates',
'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this
news release are subject to the satisfactory
progress of research which is, by its very nature, unpredictable. Forward projections reflect
management's best estimates based on
information available at the time of issue.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IMSEAASPFFKPEAE
|